Physician profile
Wei Tang
NPI 1851516876
$5,074.13
in general payments reported to CMS, 2019-2025
55 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $46.94 · 2021: $406 · 2022: $1,052 · 2023: $1,136 · 2024: $1,266 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.36 | 2021-2025 | Botox, Qulipta |
| Ucb, INC. | $397.52 | 2022-2025 | Rystiggo, Fintepla, Briviact |
| Lilly USA, LLC | $277.13 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $276.79 | 2020-2025 | Vumerity, Skyclarys, Tysabri |
| Emd Serono, INC. | $205.32 | 2023-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $179.89 | 2021-2024 | |
| Grifols USA, LLC | $173.97 | 2021-2025 | Gamunex-C |
| Genentech USA, INC. | $168.79 | 2022-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $154.24 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genzyme Corporation | $138.56 | 2021-2025 | |
| Novo Nordisk INC | $134.18 | 2019-2020 | |
| Pfizer INC. | $130.47 | 2023-2025 | |
| Sk Life Science, INC. | $121.76 | 2021-2023 | |
| Boston Scientific Corporation | $107.71 | 2021-2023 | Vercise |
| Celgene Corporation | $107.43 | 2023-2025 | Zeposia |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.